Attached files

file filename





Washington, D.C. 20549







Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934.

Date of Report: January 10, 2013

(Date of earliest event reported)



SciClone Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)




Delaware   0-19825   94-3116852

(State or other jurisdiction

of incorporation)



File Number)


(IRS Employer

Identification Number)

950 Tower Lane, Suite 900, Foster

City, CA

(Address of principal executive offices)   (Zip Code)

(650) 358-3456

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if changed since last report)



Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))




Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

(d) On January 10, 2013, the Corporate Governance Committee of the Board of Directors of SciClone Pharmaceuticals, Inc. (the “Company”), acting on the authority of the Board of Directors of the Company (the “Board”), appointed Simon Li to serve as a member of the Board, effective immediately. Mr. Li’s term will expire at the 2013 annual meeting of stockholders, and he will be subject to the election of the Company’s stockholders at that meeting. In connection with his appointment, Mr. Li has not yet been appointed to serve as a member of any committee of the Board.

A copy of the Company’s press release announcing Mr. Li’s appointment is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein.


Item 9.01 Financial Statements and Exhibits.

(d) The following exhibits are filed herewith:


Exhibit 99.1    Press release dated January 14, 2013.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: January 14, 2013     SCICLONE PHARMACEUTICALS, INC.
    By:   /s/ Gary S. Titus
      Gary S. Titus

Chief Financial Officer and

Senior Vice President, Finance

Exhibit Index


Exhibit No.



99.1    Press release dated January 14, 2013.